Alpha Cognition Inc
Research Alpha Cognition Inc (ACOG) on Bullrun: market cap USD 212.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerACOG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 212.30M
- Financial periodQ1 2026
- RevenueUSD 3.53M
- Net income-USD 6.48M
- Free cash flow-USD 11.80M
- Gross margin92.3%
Valuation Snapshot
latest market cap is USD 212.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 10.22M | -USD 20.67M | -USD 20.67M | 94.1% | -1.18 | USD 66.05M | n/a | USD 62.53M |
| FY2024 | USD 0 | -USD 14.79M | -USD 7.78M | n/a | -2.04 | USD 48.55M | USD 911.46K | USD 39.09M |
| FY2023 | n/a | -USD 13.76M | n/a | n/a | -3.84 | USD 1.40M | USD 1.22M | -USD 4.70M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 212.30M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 141.32M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 94.36M | n/a | n/a | n/a |
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alpha Cognition Inc's market cap?
Alpha Cognition Inc's market capitalization is USD 212.30M.
What does Alpha Cognition Inc do?
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease.